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Introduction
Multiple sclerosis (MS) is a complex inflammatory 
disease in which autoreactive lymphocytes infiltrate 
the central nervous system (CNS). Sphingosine 
1-phosphate (S1P) is a phospholipid involved in lym-
phocyte migration and other physiological processes. 
The initial S1P receptor modulator approved for treat-
ing relapsing multiple sclerosis (RMS), fingolimod 
targets four of the five S1P receptors: S1P1, S1P3, 
S1P4, and S1P5.1,2 Functional antagonism of S1P1 pre-
vents the release of immune cells from lymph nodes, 
while S1P5 modulation may be neuroprotective.3–5
Ozanimod is a once-daily, oral immunomodulator 
that selectively targets S1P1 and S1P5. In the placebo-
controlled, phase II portion (Part A) of RADIANCE 
(NCT01628393), ozanimod hydrochloride (HCl) 0.5 
and 1 mg were associated with significant reductions 
in mean cumulative number of gadolinium-enhancing 
lesions and new/enlarging T2-hyperintense lesions 
over weeks 12–24 relative to placebo, as well as 
numerical, dose-dependent decreases in annualized 
relapse rate (ARR) in participants with RMS.6 No 
serious cardiac events, serious infections, or macular 
edema were reported. We report results for an 
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Background: Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate recep-
tors 1 and 5.
Objective: Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis.
Methods: In the RADIANCE Part A phase II study (NCT01628393), participants with relapsing multiple 
sclerosis were randomized (1:1:1) to once-daily ozanimod hydrochloride (0.5 or 1 mg) or placebo. After 
24 weeks, participants could enter a 2-year, dose-blinded extension. Ozanimod-treated participants con-
tinued their assigned dose; placebo participants were re-randomized (1:1) to ozanimod hydrochloride 0.5 
or 1 mg (equivalent to ozanimod 0.46 and 0.92 mg).
Results: A total of 223 (89.6%) of the 249 participants completed the blinded extension. At 2 years of the 
extension, the percentage of participants who were gadolinium-enhancing lesion-free ranged from 86.5% 
to 94.6%. Unadjusted annualized relapse rate during the blinded extension (week 24—end of treatment) 
was 0.32 for ozanimod hydrochloride 0.5 mg → ozanimod hydrochloride 0.5 mg, 0.18 for ozanimod 
hydrochloride 1 mg → ozanimod hydrochloride 1 mg, 0.30 for placebo → ozanimod hydrochloride 0.5 
mg, and 0.18 for placebo → ozanimod hydrochloride 1 mg. No second-degree or higher atrioventricular 
block or serious opportunistic infection was reported.
Conclusion: Ozanimod demonstrated sustained efficacy in participants continuing treatment up to 2 years 
and reached similar efficacy in participants who switched from placebo; no unexpected safety signals 
emerged.
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additional 2 years of participation in the blinded 
extension of RADIANCE Part A.
Methods
Study design and participants
The design of RADIANCE Part A was previously 
described.6 Briefly, RADIANCE Part A was a multi-
center, randomized, double-blind, placebo-controlled, 
phase II study of participants with RMS diagnosed 
per the 2010 McDonald criteria.7 Study participants 
were aged 18–55 years, with an Expanded Disability 
Status Scale (EDSS) score 0–5.0 and ⩾1 relapse in 
the 12 months prior to enrollment or ⩾1 relapse in the 
prior 24 months plus ⩾1 gadolinium-enhancing mag-
netic resonance imaging (MRI) lesion in the previous 
12 months. Those with progressive MS or disease 
duration >15 years and EDSS score ⩽2.0 were 
excluded.
Eligible participants were randomized (1:1:1) to once-
daily ozanimod HCl 0.5 mg (equivalent to ozanimod 
0.46 mg), ozanimod HCl 1 mg (equivalent to ozanimod 
0.92 mg), or placebo for 24 weeks. At week 24, study 
participants could enter a 2-year, dose-blinded exten-
sion in which participants originally randomized to oza-
nimod HCl continued their assigned dose (ozanimod 
HCl 0.5 mg → ozanimod HCl 0.5 mg and ozanimod 
HCl 1 mg → ozanimod HCl 1 mg groups), and those 
originally administered placebo were re-randomized 
(1:1) to ozanimod HCl 0.5 mg (placebo → ozanimod 
HCl 0.5 mg group) or 1 mg (placebo → ozanimod HCl 
1 mg group), as shown in Figure 1. Randomization was 
stratified by country and performed centrally through 
an interactive voice response system using a computer-
generated sequence programmed by an independent, 
unmasked, statistical team at the contract research 
organization (Pharmaceutical Product Development). 
During the extension, the sponsor and contract research 
organization were unblinded to treatment assignment, 
while investigators and participants remained blinded. 
A dual assessor approach, with separate treating and 
EDSS-examining investigators, was used to reduce 
potential unblinding. A core-imaging facility (NeuroRx 
Research, Montreal, Canada), blinded to treatment and 
other outcomes, performed MRI measurements.
All participants, including those originally randomized 
to ozanimod HCl during the placebo-controlled period, 
underwent dose escalation with ozanimod HCl at 
week 24 (baseline for the blinded extension) over 
7 days (0.25 mg on days 1–4, 0.5 mg on days 5–7, and 
then assigned dose starting on day 8) at the beginning 
of the blinded extension to maintain blinding.
Standard protocol approvals, registrations, and 
participant consents
The RADIANCE Part A extension was approved by 
the institutional review board/ethics committee at each 
participating site. The study protocol conformed to 
Figure 1. RADIANCE Part A design.
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Good Clinical Practice guidelines and the principles 
outlined in the Declaration of Helsinki. All participants 
provided written informed consent. The study is regis-
tered at ClinicalTrials.gov (NCT01628393).
Assessments
During the blinded extension, participants were 
examined every 12 weeks. MRI was performed at 
entry to and at 6 months, 1 year, and 2 years of the 
blinded extension. A blinded treating physician super-
vised clinical management of the participant, includ-
ing treatment-emergent adverse events (TEAEs). An 
independent, blinded EDSS evaluator performed the 
neurological examinations and completed the EDSS 
assessment. Efficacy endpoints included mean num-
ber of gadolinium-enhancing lesions, proportions of 
participants free of gadolinium-enhancing lesions, 
mean number of new or enlarging T2-hyperintense 
lesions on brain MRI, and unadjusted ARR.
Safety evaluations included the incidence and type of 
TEAEs, serious TEAEs, TEAEs leading to treatment 
discontinuation, pulmonary function tests, optical 
coherence tomography, and laboratory testing. TEAEs 
of special interest included infections, bradycardia, 
heart conduction abnormalities, abnormal pulmonary 
function tests, macular edema, hepatic effects, and 
malignancies.
At week 24 (baseline of the blinded extension), all 
participants were monitored for 6 hours after treat-
ment (hourly vital signs and electrocardiograms 
before and 6 hours after treatment initiation in the 
blinded extension). Dermatologic exams were per-
formed by the investigator at screening and every 
6 months thereafter; any participant with suspicious 
findings was referred to a dermatologist.
Statistical analysis
Descriptive statistics were used to describe outcomes 
in the intent-to-treat population during the blinded 
extension. Demographic characteristics and safety 
data were pooled by ozanimod HCl-dose group (0.5 
or 1 mg). Efficacy was examined in the dose sub-
groups as described above.
Results
Participant disposition
In total, 97.7% (252/258) of the participants com-
pleted the 24-week placebo-controlled period (ozani-
mod HCl 0.5 mg, n = 85; ozanimod HCl 1 mg, n = 82; 
placebo, n = 85). Three participants declined to enter 
the blinded extension. A total of 126 participants 
received ozanimod HCl 0.5 mg, and 123 received 
ozanimod HCl 1 mg during the blinded extension 
(Figure 2) between 1 May 2013 and 2 May 2016. 
Demographics and disease characteristics of partici-
pants in the blinded extension were similar to the 
baseline of the core period6 and across treatment 
groups (Table 1). Overall, 89.6% (223/249) of par-
ticipants in RADIANCE Part A who continued to the 
blinded extension completed an additional 2 years, 
with 11.1% (14/126) and 9.8% (12/123) of those ran-
domized to ozanimod HCl 0.5 and 1 mg, respectively, 
discontinuing study treatment prior to year 2. The 
reasons for treatment discontinuation are summa-
rized in Figure 2.
Efficacy
The mean number of gadolinium-enhancing lesions 
remained low in participants who continued ozani-
mod HCl throughout the placebo-controlled6 and 
blinded extension periods (Figure 3(a)). Among par-
ticipants initially assigned to placebo who were re-
randomized to ozanimod HCl, the mean number of 
gadolinium-enhancing lesions decreased between 
entry into the blinded extension at year 1 and remained 
low at year 2. At entry into the blinded extension, the 
proportion of participants free of gadolinium-enhanc-
ing lesions was 84.7% for ozanimod HCl 0.5 mg → 
ozanimod HCl 0.5 mg, 87.7% for ozanimod HCl 1 mg 
→ ozanimod HCl 1 mg, 58.5% for placebo → ozani-
mod HCl 0.5 mg, and 69.0% for placebo → ozanimod 
HCl 1 mg; the proportions of participants free of gad-
olinium-enhancing lesions ranged from 91.1% to 
92.9% at year 1 and from 86.5% to 94.6% at year 2 
(Figure 3(b)). Ozanimod HCl showed a dose- 
dependent trend in reducing the mean number of new 
or enlarging T2 lesions (Figure 3(c)) from entry into 
the blinded extension to year 1 and from year 1 to year 
2. The effects of ozanimod HCl on the unadjusted 
ARR seen during the placebo-controlled period were 
maintained during the blinded extension (Figure 3(d)) 
for participants continuing ozanimod HCl and 
decreased over the study period for those participants 
initially randomized to placebo (Figure 3(d)). 
Unadjusted ARR during the blinded extension was 
0.32 for ozanimod HCl 0.5 mg → ozanimod HCl 
0.5 mg, 0.18 for ozanimod HCl 1 mg → ozanimod 
HCl 1 mg, 0.30 for placebo → ozanimod HCl 0.5 mg, 
and 0.18 for placebo → ozanimod HCl 1 mg. Mean 
EDSS remained stable during the blinded extension 
period. Mean (standard deviation) change from base-
line of the blinded extension at year 2 was 0.2 (0.85) 
for the ozanimod HCl 0.5 mg → ozanimod HCl 
Multiple Sclerosis Journal 25(9)
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0.5 mg group, 0.1 (0.64) for the ozanimod HCl 1 mg 
→ ozanimod HCl 1 mg group, 0.3 (0.76) for the pla-
cebo → ozanimod HCl 0.5 mg group, and 0.2 (0.67) 
for the placebo → ozanimod HCl 1 mg group.
Safety
Safety data are summarized in Table 2 and 
Supplementary Table 1. The most common TEAEs 
associated with ozanimod HCl were nasopharyngi-
tis, upper respiratory tract infection, and increased 
alanine aminotransferase (ALT). A total of 4.9% 
(12/247) of participants had increases in ALT ⩾3-
times the upper limit of normal (ULN; ozanimod 
HCl 0.5 mg, n = 4; ozanimod HCl 1 mg, n = 8). Of 
these participants, two (ozanimod HCl 0.5 mg, n = 1; 
ozanimod HCl 1 mg, n = 1) had concurrent aspartate 
aminotransferase (AST) elevations, while one par-
ticipant, treated with ozanimod HCl 1 mg, had an 
isolated AST elevation. There were no reports of 
serious opportunistic infections during the blinded 
extension. No clinically significant abnormalities in 
pulmonary function tests and no cases of macular 
edema or malignancy were reported during the 
blinded extension. Four participants discontinued 
treatment due to a TEAE during the 2-year blinded 
extension (Table 2). These discontinuations were all 
attributable to increased transaminases and were 
protocol-specified (participants with confirmed 
ALT or AST levels >5-times the ULN were required 
to permanently discontinue study treatment). All 
four participants recovered after discontinuation of 
ozanimod HCl.
Figure 2. Disposition.
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A total of 12 participants receiving ozanimod HCl 
0.5 mg experienced ⩾1 serious TEAE, including 
acute myocardial infarction, (n = 1; 18 months after 
first dose in a participant who was 43 years old at ran-
domization and had a medical history of lupus and 
hypertension) and hepatitis (n = 1; in a participant 
with a recent history of multiple bee stings and who 
was negative for viral hepatitis etiologies and anti-
nuclear antibodies; Table 2; Supplementary Table 2). 
Nine participants receiving ozanimod HCl 1 mg 
reported a serious TEAE, including a case of moder-
ate pancytopenia that resolved without interruption of 
treatment. No serious TEAE occurred in more than 
one participant, and none was considered related to 
ozanimod HCl.
The maximum mean decrease in heart rate from pre-
dose baseline of the extension was 0.6 bpm, which 
was observed at 4 hours post-treatment on the first 
day of dose escalation at entry into the blinded exten-
sion in the placebo → ozanimod HCl 0.5 mg group; in 
participants continuing ozanimod HCl, mean heart 
rate did not decrease relative to baseline. One partici-
pant, randomized to placebo → ozanimod HCl 1 mg, 
experienced a decline in heart rate per vital sign meas-
urement to below 45 bpm (specifically, 44 bpm), 
which was asymptomatic; this participant had a base-
line pre-dose heart rate of 55 bpm. No participant who 
switched from placebo to ozanimod HCl had a 
decrease in heart rate of >20 bpm from pre-dose base-
line during hours 1‒6 on the first day of the blinded 
extension. There were no reports of second-degree or 
higher atrioventricular block.
Hypertension was reported in 7.9% (10/126) of par-
ticipants in the ozanimod HCl 0.5 mg group and 3.3% 
(5/123) of participants in the 1 mg group, with one 
case in the 0.5 mg group considered to be possibly 
related to study drug. There was one case of hyperten-
sion that was considered serious but unrelated to 
study drug in a participant (ozanimod HCl 0.5 mg 
group) with pre-existing hypertension who was hospi-
talized for further cardiac evaluation and medication 
adjustment. Herpes zoster was reported in five partici-
pants (ozanimod HCl 0.5 mg, n = 3; ozanimod HCl 
1 mg, n = 2), although immunity was a requirement for 
enrollment. No case was serious and none led to per-
manent discontinuation of study drug. No seizures 
were reported during the study. No dermatologic can-
cers were observed.
During ozanimod exposure, four participants (all 
treated with ozanimod HCl 1 mg) had absolute lym-
phocyte counts <200 cells/µL, which were observed 
at weeks 12 and 48 (n = 1), 24 (n = 1), and 72 (n = 2) of 
the blinded extension (no participant had absolute 
lymphocyte counts <200 cells/µL during the core 
period of the study8). The absolute lymphocyte count 
Table 1. Demographics and disease characteristics of the blinded extension population at study entry.
Placebo → 
ozanimod HCl 
0.5 mg, (n = 41)
Ozanimod HCl 
0.5 mg → ozanimod 
HCl 0.5 mg, (n = 85)
Placebo → 
ozanimod HCl 1 mg, 
(n = 42)
Ozanimod HCl 1 mg 
→ ozanimod HCl 
1 mg, (n = 81)
Mean age (SD), years 41 (8.01) 38.1 (9.26) 36.9 (8.69) 38.5 (9.90)
Female, n (%) 30 (73.2) 58 (68.2) 30 (71.4) 57 (70.4)
White, n (%) 41 (100) 83 (97.6) 42 (100) 81 (100)
Eastern Europe, n (%) 38 (92.7) 78 (91.8) 36 (85.7) 74 (91.4)
Mean time since MS symptom onset (SD), 
years
9.0 (7.05) 6.0 (6.49) 7.0 (7.05) 6.2 (5.81)
Mean time since MS diagnosis (SD), years 5.3 (5.19) 2.8 (5.02) 3.7 (5.11) 3.6 (4.46)
Mean EDSS score (SD) 2.7 (1.19) 2.9 (1.29) 2.9 (1.38) 2.8 (1.18)
Mean relapses in the previous 12 months, n 
(SD)
1.3 (0.68) 1.4 (0.95) 1.4 (0.62) 1.3 (0.71)
Mean relapses in the previous 24 months, n 
(SD)
2.0 (1.22) 2.0 (1.69) 1.7 (0.75) 1.8 (1.05)
Mean gadolinium-enhancing lesions, n (SD) 1.8 (3.73) 0.9 (1.43) 0.6 (1.38) 1.4 (2.78)
Participants free of gadolinium-enhancing 
lesions, n (%)
28 (68.3) 51 (60.0) 30 (71.4) 51 (63.0)
Participants who received prior MS 
medication, n (%)
18 (43.9) 19 (22.4) 12 (28.6) 18 (22.2)
EDSS: Expanded Disability Status Scale; MS: multiple sclerosis; SD: standard deviation.
Demographic and baseline characteristics at entry into the double-blind, placebo-controlled phase of RADIANCE Part A.
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reductions below 200 cells/µL were transient, with 
none associated with infection or leading to study dis-
continuation. Three participants, all treated with oza-
nimod HCl 0.5 mg, had absolute neutrophil counts 
<1000 cells/µL, one at baseline, one at week 48, and 
one at week 96 of the blinded extension.
Discussion
In the blinded extension of the phase II portion of 
RADIANCE, both doses of ozanimod HCl (0.5 and 
1 mg) demonstrated continued efficacy over 2 years, 
as shown by low levels of MRI lesion activity and low 
unadjusted ARR, with apparent greater efficacy on 
Figure 3. Efficacy outcomes: (a) mean number of gadolinium-enhancing lesions at year 1 and year 2 of the blinded 
extension, (b) proportions of participants free of gadolinium-enhancing lesions during the blinded extension, (c) mean 
number of new or enlarging T2 lesions over the entire study, and (d) unadjusted ARR over the entire study.
ARR: annualized relapse rate; GdE: gadolinium-enhancing; SEM: standard error of the mean.
Table 2. Safety summary.
Core period and blinded extension
 Ozanimod HCl 
0.5 mg, (n = 126)
Ozanimod HCl 
1 mg, (n = 123)
Participants with ⩾1 TEAE, n (%) 99 (78.6) 93 (75.6)
Participants with ⩾1 treatment-related TEAE, n (%) 5 (4.0) 4 (3.3)
Participants with ⩾1 serious TEAE, n (%) 12 (9.5) 9 (7.3)
Participants with ⩾1 TEAE leading to treatment 
discontinuation, n (%)
3 (2.4) 1 (0.8)
Treatment-related deaths, n (%) 0 (0) 0 (0)
TEAE: treatment-emergent adverse event.
JA Cohen, G Comi et al.
journals.sagepub.com/home/msj 1261
both MRI and clinical disease measures for ozanimod 
HCl 1 mg versus ozanimod HCl 0.5 mg. In addition, 
the efficacy observed in participants who initially 
received placebo approximated that observed in par-
ticipants who received ozanimod HCl continuously 
throughout the placebo-controlled portion of the 
study and the blinded extension. Consistent with the 
24-week placebo-controlled treatment period,6 gado-
linium-enhancing and new or enlarging T2 lesion 
numbers remained low in all four treatment groups 
during the 2-year blinded extension.
Safety plays a major role in treatment preference 
among individuals with MS,9 and adverse events (e.g. 
injection reactions and flu-like symptoms with inject-
able therapies and gastrointestinal side effects, head-
ache, heart rate effects, and macular edema with oral 
therapies) are among the most common reasons for 
the discontinuation of MS treatments.10 The use of 
ozanimod HCl for over 2 years was well tolerated, 
with few participants discontinuing for side effects or 
safety reasons. TEAEs during the 2-year blinded 
extension were consistent with those seen during the 
placebo-controlled period, with no apparent increase 
over time or differences between ozanimod HCl 0.5 
and 1 mg. In the blinded extension period, 4.9% of 
participants receiving ozanimod HCl experienced 
increases in ALT ⩾3-times the ULN, with the major-
ity of ALT elevations occurring in participants who 
switched from placebo. Most cases of elevated liver 
enzymes were transient and did not require discon-
tinuation of ozanimod HCl. Based on protocol 
requirements, four participants discontinued from the 
study with an ALT ⩾5-times ULN; all recovered after 
drug discontinuation.
Ozanimod was administered in a dose escalation regi-
men. In the RADIANCE Part A blinded extension, 
there were no reports of clinically significant cardiac 
conduction abnormalities associated with ozanimod 
HCl, including no second-degree or higher atrioven-
tricular block, and no clinically meaningful bradycar-
dia was observed, consistent with the results of the 
placebo-controlled period.6 It should be noted that 
individuals with certain clinically relevant cardiovas-
cular conditions were excluded from the study,6 and 
<20% of participants had a history of cardiovascular 
disorders. Additional studies will help to further 
define the safety profile of ozanimod.
Results of extension studies are sometimes biased by 
participant attrition. However, this analysis benefited 
from high retention, with 88.9% of participants rand-
omized to ozanimod HCl 0.5 mg and 90.2% of partici-
pants administered ozanimod HCl 1 mg completing 
2 years of treatment. The participant population in 
this study was similar to that of other phase II trials 
of participants with MS administered other selective 
S1P receptor modulators.11 Limitations of these data 
include lack of a control arm during the blinded 
extension, relatively small sample size, and a pre-
dominantly white, Eastern European population. 
The phase III portion of RADIANCE (Part B, 
NCT02047734) is larger, comprising 1313 partici-
pants with RMS randomized (1:1:1) to ozanimod 
HCl 0.5 mg, ozanimod HCl 1 mg, or intramuscular 
interferon beta-1a for 24 months. In addition, 
SUNBEAM (NCT02294058), a similarly designed 
phase III study, enrolled 1346 participants with 
RMS. Those participating in SUNBEAM received 
ozanimod HCl 0.5 mg, ozanimod HCl 1 mg, or intra-
muscular interferon beta-1a for at least 12 months. 
Together, these two phase III studies will provide 
comprehensive data on the benefits and risks of this 
potential new treatment for RMS.
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